These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21801593)

  • 21. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1.
    Harris AK; Hutchinson JR; Sachidanandam K; Johnson MH; Dorrance AM; Stepp DW; Fagan SC; Ergul A
    Diabetes; 2005 Sep; 54(9):2638-44. PubMed ID: 16123352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of endothelin receptor A and B antagonism on behavioral outcome following traumatic brain injury.
    Reynolds CA; Schafer S; Pirooz R; Marinica A; Chbib A; Bedford C; Fronczak M; Rafols JA; Kuhn D; Kreipke CW
    Neurol Res; 2011 Mar; 33(2):197-200. PubMed ID: 21801595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EndothelinA-endothelinB receptor cross-talk in rat basilar artery in situ.
    Yoon S; Zuccarello M; Rapoport RM
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Apr; 385(4):437-41. PubMed ID: 22258095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation.
    Banes-Berceli AK; Ketsawatsomkron P; Ogbi S; Patel B; Pollock DM; Marrero MB
    Am J Physiol Heart Circ Physiol; 2007 Aug; 293(2):H1291-9. PubMed ID: 17526654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual endothelin receptor antagonism prevents remodeling of resistance arteries in diabetes.
    Sachidanandam K; Portik-Dobos V; Kelly-Cobbs AI; Ergul A
    Can J Physiol Pharmacol; 2010 Jun; 88(6):616-21. PubMed ID: 20628426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease.
    Feng HQ; Weymouth ND; Rockey DC
    Am J Physiol Gastrointest Liver Physiol; 2009 Jul; 297(1):G27-33. PubMed ID: 19299580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microvascular versus macrovascular dysfunction in type 2 diabetes: differences in contractile responses to endothelin-1.
    Sachidanandam K; Harris A; Hutchinson J; Ergul A
    Exp Biol Med (Maywood); 2006 Jun; 231(6):1016-21. PubMed ID: 16741041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective endothelin ETA and dual ET(A)/ET(B) receptor blockade improve endothelium-dependent vasodilatation in patients with type 2 diabetes and coronary artery disease.
    Rafnsson A; Shemyakin A; Pernow J
    Life Sci; 2014 Nov; 118(2):435-9. PubMed ID: 24607773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelin ET(B) receptors in arteries and veins: multiple actions in the vein.
    Tykocki NR; Gariepy CE; Watts SW
    J Pharmacol Exp Ther; 2009 Jun; 329(3):875-81. PubMed ID: 19297422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endothelin antagonism uncovers insulin-mediated vasorelaxation in vitro and in vivo.
    Verma S; Yao L; Stewart DJ; Dumont AS; Anderson TJ; McNeill JH
    Hypertension; 2001 Feb; 37(2):328-33. PubMed ID: 11230293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade.
    Spiers JP; Kelso EJ; Siah WF; Edge G; Song G; McDermott BJ; Hennessy M
    J Hypertens; 2005 Sep; 23(9):1717-24. PubMed ID: 16093917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model.
    Herrmann E; Tiemann A; Eltze E; Bolenz C; Bremer C; Persigehl T; Hertle L; Wülfing C
    J Cancer Res Clin Oncol; 2009 Oct; 135(10):1455-62. PubMed ID: 19430814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Internal pudendal artery from type 2 diabetic female rats demonstrate elevated endothelin-1-mediated constriction.
    Allahdadi KJ; Hannan JL; Ergul A; Tostes RC; Webb RC
    J Sex Med; 2011 Sep; 8(9):2472-83. PubMed ID: 21718448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model.
    Battistini B; Verreault M; Ayach B; Blouin A; Cernacek P; Jeng AY; Wessale J; Opgenorth T; Tsang J
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S386-9. PubMed ID: 15838327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia.
    Best PJ; McKenna CJ; Hasdai D; Holmes DR; Lerman A
    Circulation; 1999 Apr; 99(13):1747-52. PubMed ID: 10190886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial.
    Rafnsson A; Böhm F; Settergren M; Gonon A; Brismar K; Pernow J
    Diabetologia; 2012 Mar; 55(3):600-7. PubMed ID: 22200728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse effects of pneumoperitoneum on renal function: involvement of the endothelin and nitric oxide systems.
    Abassi Z; Bishara B; Karram T; Khatib S; Winaver J; Hoffman A
    Am J Physiol Regul Integr Comp Physiol; 2008 Mar; 294(3):R842-50. PubMed ID: 18160528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelin-mediated in vivo pressor responses following TRPV1 activation.
    Ohanyan VA; Guarini G; Thodeti CK; Talasila PK; Raman P; Haney RM; Meszaros JG; Damron DS; Bratz IN
    Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H1135-42. PubMed ID: 21705674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective in vivo antagonism of endothelin receptors in transforming growth factor-beta1 transgenic mice that mimic the vascular pathology of Alzheimer's disease.
    Papadopoulos P; Ongali B; Hamel E
    Can J Physiol Pharmacol; 2010 Jun; 88(6):652-60. PubMed ID: 20628431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury.
    Zager RA; Johnson AC; Andress D; Becker K
    Kidney Int; 2013 Oct; 84(4):703-12. PubMed ID: 23698233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.